Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Retained Earnings (2022 - 2025)

Atara Biotherapeutics' Retained Earnings history spans 4 years, with the latest figure at -$2.0 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 25273412.5% year-over-year to -$2.0 billion; the TTM value through Dec 2025 reached -$2.0 billion, down 25273412.5%, while the annual FY2025 figure was -$2.0 billion, 25273412.5% down from the prior year.
  • Retained Earnings reached -$2.0 billion in Q4 2025 per ATRA's latest filing, roughly flat from -$2.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $22000.0 in Q3 2024 to a low of -$2.0 billion in Q4 2025.
  • Average Retained Earnings over 4 years is -$762.6 million, with a median of -$1.8 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: soared 103.92% in 2024, then crashed 25273412.5% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$1.7 billion in 2022, then surged by 99.99% to -$204000.0 in 2023, then skyrocketed by 103.92% to $8000.0 in 2024, then plummeted by 25273412.5% to -$2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Retained Earnings are -$2.0 billion (Q4 2025), -$2.0 billion (Q3 2025), and $8000.0 (Q4 2024).